Attached files

file filename
XML - IDEA: XBRL DOCUMENT - CytoCore IncR22.htm
EXCEL - IDEA: XBRL DOCUMENT - CytoCore IncFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - CytoCore IncR6.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR9.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR2.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR31.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR33.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR35.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR28.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR32.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR37.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR30.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR29.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR25.htm
EX-32.1 - EXHIBIT 32.1 - CytoCore Incv326519_ex32-1.htm
EX-31.1 - EXHIBIT 31.1 - CytoCore Incv326519_ex31-1.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR5.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR1.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR4.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR3.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR7.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR24.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR19.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR20.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR27.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR21.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR36.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR12.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR13.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR14.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR16.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR17.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR10.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR34.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR18.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR38.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR23.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR15.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR26.htm
10-Q - FORM 10-Q - CytoCore Incv326519_10q.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR11.htm
v2.4.0.6
Basis of Presentation
9 Months Ended
Sep. 30, 2012
Basis of Presentation [Abstract]  
Basis of Presentation
Note 2. Basis of Presentation

 

The consolidated financial statements for the periods ended September 30, 2012 and 2011 included herein are unaudited. Such consolidated financial statements reflect, in the opinion of management, all adjustments necessary to present fairly the financial position and results of operations as of and for the periods indicated. All such adjustments are of a normal recurring nature except for the write off of certain payables which are no longer valid due to the lapsing of the statute of limitations (see Note 8) and the settlement of other payables. These interim results are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2012 or for any other period. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The Company believes that the disclosures are adequate to make the interim information presented not misleading. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, as filed with the SEC on April 16, 2012.

 

The tabular information disclosed in the notes are reported in thousands of dollars except for share and per share amounts.

 

The Company’s comprehensive income (loss) is extremely immaterial and therefore the Company has not presented a separate statement of comprehensive income (loss) with its financial statements.

 

The Company’s comprehensive net loss is as follows:

    Nine months ended     Three months ended  
    September 30,
2012
    September 30,
2011
    September 30,
2012
    September 30,
2011
 
    (unaudited)     (unaudited)  
Net loss applicable to common stockholder   $ (1,208 )   $ (1,749 )   $ (53 )   $ (627 )
Foreign currency adjustment   $     $ (1 )   $     $  
Comprehensive net loss applicable to common stockholders   $ (1,208 )   $ (1,750 )   $ (53 )   $ (627 )
                                 
Basic and diluted comprehensive net loss per common share   $ (0.02 )   $ (0.03 )   $ (0.00 )   $ (0.01 )
Basic and diluted weighted average number of common shares outstanding     70,278,553       55,644,245       72,964,624       59,759,909